Literature DB >> 37989

Neurotransmitter-related enzymes in senile dementia of the Alzheimer type.

P Davies.   

Abstract

Choline acetyltransferase (ChAT), acetylcholinesterase (AChE) and glutamic acid decarboxylase (GAD) activities were measured in 20 brain regions from autopsied control and senile dementia of the Alzheimer type (SDAT) cases. Large, widespread reductions in the activities of ChAT and AChE were found in tissues from SDAT cases, while GAD activities were reduced in 3 of the 20 regions investigated. AChE activity in cerebrospinal fluid from SDAT cases was similar to that found in samples from non-demented patients.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 37989     DOI： 10.1016/0006-8993(79)90336-6

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  70 in total

1.  The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors:  Richard B Silverman
Journal:  J Med Chem       Date:  2012-01-10       Impact factor: 7.446

2.  Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease.

Authors:  Sylvia E Perez; Damianka P Getova; Bin He; Scott E Counts; Changiz Geula; Laurent Desire; Severine Coutadeur; Helene Peillon; Stephen D Ginsberg; Elliott J Mufson
Journal:  Am J Pathol       Date:  2011-12-03       Impact factor: 4.307

3.  Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease.

Authors:  Denise Harold; Timothy Peirce; Valentina Moskvina; Amanda Myers; Susan Jones; Paul Hollingworth; Pamela Moore; Simon Lovestone; John Powell; Catherine Foy; Nicola Archer; Sarah Walter; Amanda Edmonson; Stephen McIlroy; David Craig; Peter A Passmore; Alison Goate; John Hardy; Michael O'Donovan; Julie Williams; Malcolm Liddell; Michael J Owen; Lesley Jones
Journal:  Hum Genet       Date:  2003-05-21       Impact factor: 4.132

4.  Studies on new, centrally active and reversible acetylcholinesterase inhibitors.

Authors:  F Arnal; L J Coté; S Ginsburg; G D Lawrence; A Naini; M Sano
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

5.  Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data.

Authors:  K J Reinikainen; P J Riekkinen; L Paljärvi; H Soininen; E L Helkala; J Jolkkonen; M Laakso
Journal:  Neurochem Res       Date:  1988-02       Impact factor: 3.996

6.  Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.

Authors:  F P Zemlan
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Molecular biology and neurobiology of choline acetyltransferase.

Authors:  P M Salvaterra
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

Review 8.  Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids.

Authors:  A A Farooqui; L Liss; L A Horrocks
Journal:  Metab Brain Dis       Date:  1988-03       Impact factor: 3.584

9.  A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease.

Authors:  D M Mann; P O Yates; B Marcyniuk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-02       Impact factor: 10.154

10.  Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multi-infarct dementia.

Authors:  E Perdahl; R Adolfsson; I Alafuzoff; K A Albert; E J Nestler; P Greengard; B Winblad
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.